• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Mesa Laboratories Inc.

    6/3/26 8:23:01 AM ET
    $MLAB
    Industrial Machinery/Components
    Industrials
    Get the next $MLAB alert in real time by email
    S-8 1 mlab20260213_s8.htm FORM S-8 mlab20260213_s8.htm

     

    As filed with the Securities and Exchange Commission on June 3, 2026

     

    Registration No. 333- 



     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     


     

    FORM S-8 

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     


     

    MESA LABORATORIES, INC.

    (Exact name of registrant as specified in its charter)

     


     

    Colorado
    (State or other jurisdiction of
    incorporation)

    0-11740

    (Commission File Number)

    84-0872291
    (I.R.S. Employer
    Identification No.)

     

    12100 West Sixth Avenue,

    Lakewood, Colorado
    (Address of principal executive offices)

     

    80228
    (Zip Code)

     

    Mesa Laboratories, Inc. Amended and Restated 2021 Equity Incentive Plan 

    (Full title of the plan)

     


     

    John Sakys
    Chief Financial Officer

    Mesa Laboratories, Inc.
    12100 West Sixth Avenue
    Lakewood, CO 80228
    303-987-8000
    (Name, address, including zip code, and telephone number,
    including area code, of agent for service)

     

    With copies to:

    John Elofson

    Davis Graham & Stubbs LLP

    3400 Walnut Street, Suite 700

    Denver, Colorado 80205

    Telephone: (303) 892-9400

     


     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☐  

    Accelerated filer

    ☒

    Non-accelerated filer

    ☐  

    Smaller reporting company

    ☐

         

    Emerging growth company

    ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     



     

     

     

    Explanatory Note

     

    This Registration Statement on Form S-8 is filed pursuant to General Instruction E to Form S-8 for the purpose of registering an additional 496,000 shares of common stock, no par value per share, of Mesa Laboratories, Inc. (the “Registrant”), which may be issued pursuant to awards under the Registrant’s Amended and Restated 2021 Equity Incentive Plan (the “2021 Plan”). In accordance with General Instruction E to Form S-8, the Registrant incorporates herein by reference the contents of the registration statements on Form S-8 filed by the Registrant with respect to the 2021 Plan on August 30, 2021 (Registration No. 333-259154) and August 30, 2023 (Registration No. 333-274263), together with all exhibits filed therewith or incorporated therein by reference to the extent not otherwise amended or superseded by the contents hereof.

     

    PART I

     

    INFORMATION REQUIRED IN THE 10(A) PROSPECTUS

     

    As permitted by the rules of the Securities and Exchange Commission (the “Commission”), this Registration Statement omits the information specified in Part I of Form S-8. The documents containing the information specified in Part I will be sent or given to the participants in the 2021 Plan as required by Rule 428(b)(1) under the Securities Act. Such documents are not being filed with the Commission as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act. Those documents, and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II hereof, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference

     

    The following documents have been filed with the Commission by the Registrant and are hereby incorporated in this registration statement by reference, excluding any disclosures therein that have been furnished and not filed:

     

     

    (a)

    The Registrant’s Annual Report on Form 10-K for the fiscal year ended March 31, 2026;

     

     

    (b)

    The information specifically incorporated by reference into the Registrant’s Annual Report on Form 10-K for the fiscal year ended March 31, 2025 from the Registrant’s definitive proxy statement on Schedule 14A; 

     

     

    (c)

    The description of the Registrant’s common stock contained in Exhibit 4.3 to the Registrant’s Annual Report on Form 10-K for the year ended March 31, 2026, and including any other amendment or report filed for the purpose of updating such description.

     

    All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), subsequent to the date of this registration statement and prior to the filing of a post-effective amendment to this registration statement indicating that all securities offered under the registration statement have been sold, or deregistering all securities then remaining unsold, shall be deemed to be incorporated by reference herein and shall be a part hereof from the respective dates of filing such documents, other than any portions of such documents that are deemed furnished under applicable Commission rules rather than filed.

     

     

     

     

    Any statement contained in a document incorporated, or deemed to be incorporated, by reference herein shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement contained herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

     

    Item 8. Exhibits

     

    Exhibit
    No.

     

    Description

    3.1

     

    Amended and Restated Articles of Incorporation of Mesa Laboratories, Inc. (incorporated by reference from Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on August 25, 2023).

    3.2

     

    Amended and Restated Bylaws of Mesa Laboratories, Inc. (incorporated by reference from Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on May 10, 2019).

    5.1

     

    Opinion of Counsel.*

    10.2.3

     

    Mesa Laboratories, Inc. Amended and Restated 2021 Equity Incentive Plan (incorporated by reference from Exhibit 10.2.3 to the Company's Quarterly Report on form 10-Q filed November 6, 2025).

    10.3.3   Form of Restricted Stock Unit Agreement, issued under the 2021 Equity Incentive Plan, as Amended. (incorporated by reference from Exhibit 10.3.3 to the Company's Form 10-K filed on June 2, 2026).
    10.3.4   Form of 2024 Performance Stock Unit Agreement, issued under the 2021 Equity Incentive Plan, as Amended. (incorporated by reference from Exhibit 10.3.4 to the Company's Form 10-K filed on June 2, 2026).
    10.3.5   Form of 2025 Performance Stock Unit Agreement, issued under the 2021 Equity Incentive Plan, as Amended. (incorporated by reference from Exhibit 10.3.5 to the Company's Form 10-K filed on June 2, 2026).
    10.3.6   Form of 2026 Performance Stock Unit Agreement, issued under the 2021 Equity Incentive Plan, as Amended. (incorporated by reference from Exhibit 10.3.6 to the Company's Form 10-K filed on June 2, 2026).

    10.3.7

     

    Form of 2021 Equity Incentive Plan Option Award Agreement (incorporated by reference from Exhibit 10.3.7 to the Company’s Form S-8 filed on August 30, 2021). 

    23.1

     

    Consent of Baker Tilly US LLP.*

    23.2   Consent of RSM US LLP.*

    23.3

     

    Consent of Counsel (included in Exhibit 5.1).*

    24.1

     

    Power of Attorney (included on the signature page hereto).*

    107

     

    Filing Fee Table.*

     

    * Filed or furnished herewith.  

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Lakewood, State of Colorado, on this 2nd day of June, 2026. 

     

    MESA LABORATORIES, INC.

     

    By:

    /s/ JOHN SAKYS

    Name:

    John Sakys

    Title:

    Chief Executive Officer

     

     

    POWER OF ATTORNEY

     

    Each of the undersigned hereby constitutes and appoints each of Siddhartha Kadia and John Sakys the undersigned’s true and lawful attorney-in-fact and agent, with full power of substitution, for the undersigned and in his name, place and stead, in any and all capacities, to sign any or all amendments or post-effective amendments to this Registration Statement, and any other instruments or documents that said attorneys-in-fact and agents may deem necessary or advisable, to enable Mesa Laboratories, Inc. to comply with the Securities Act of 1933, as amended, and any requirements of the Securities and Exchange Commission in respect thereof, and to file the same, with all exhibits thereto, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents and each of them full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that each such attorney- in-fact and agent, or his substitute, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

     

    Title

     

    Date

             

    /s/ JOHN SULLIVAN, PH.D.

    John Sullivan

     

    Chairman of the Board of Directors

     

    June 2, 2026

             

    /s/ SIDDHARTHA KADIA, PH.D.

    Siddhartha Kadia

     

    Chief Executive Officer, President, and Director

      June 2, 2026
             

    /s/ JOHN SAKYS

    John Sakys

     

    Chief Financial Officer, Vice President, and Treasurer

      June 2, 2026
             

    /s/ JENNIFER ALLTOFT

    Jennifer Alltoft

     

    Director         

      June 2, 2026
             

    /s/ MARK CAPONE

    Mark Capone

      Director   June 2, 2026
             

    /s/ SHANNON HALL

    Shannon Hall

     

    Director         

      June 2, 2026
             

    /s/ SHIRAZ LADIWALA

    Shiraz Ladiwala

     

    Director

      June 2, 2026
             

    /s/ TONY TRIPENY

    Tony Tripeny

     

    Director

      June 2, 2026

     

     
    Get the next $MLAB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MLAB

    DatePrice TargetRatingAnalyst
    8/7/2025$67.00Underweight → Equal Weight
    Wells Fargo
    8/28/2024$120.00Underweight
    Wells Fargo
    1/4/2024$100.00 → $125.00In-line → Outperform
    Evercore ISI
    More analyst ratings

    $MLAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MESA LABS DECLARES QUARTERLY DIVIDEND

    Lakewood, Colo., July 06, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 15, 2026, to shareholders of record at the close of business on August 31, 2026. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, inc

    7/6/26 9:50:22 AM ET
    $MLAB
    Industrial Machinery/Components
    Industrials

    Mesa Labs Announces Fourth Quarter and Fiscal Year 2026 Results

    LAKEWOOD, Colo., May 27, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) ("Mesa" or "the Company"), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its fourth fiscal quarter ("4Q26") and fiscal year ("FY26") ended March 31, 2026 (amounts in thousands). 4Q26 Financial Summary – (comparisons are versus the same prior year period) Revenues increased 2.6%Non-GAAP organic and core organic revenues1 growth was 2.6% and (0.6)%, respectivelyOperating income increased 87% to $2,748Non-GAAP adjusted operating income ("AOI") excluding unusual items2 increased 49.2% and was 28.7% as a percentag

    5/27/26 8:00:00 AM ET
    $MLAB
    Industrial Machinery/Components
    Industrials

    Mesa Laboratories, Inc. to Announce Fourth Quarter and Full Fiscal Year Results on May 27, 2026

    LAKEWOOD, Colo., May 05, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the fourth quarter and the fiscal year ended March 31, 2026 at approximately 6:00 A.M. Eastern Time (ET) on Wednesday, May 27, 2026. About Mesa LaboratoriesMesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world. Mesa Laboratories C

    5/5/26 1:39:00 PM ET
    $MLAB
    Industrial Machinery/Components
    Industrials

    $MLAB
    Leadership Updates

    Live Leadership Updates

    View All

    Mesa Labs Announces Fourth Quarter and Fiscal Year 2026 Results

    LAKEWOOD, Colo., May 27, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) ("Mesa" or "the Company"), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its fourth fiscal quarter ("4Q26") and fiscal year ("FY26") ended March 31, 2026 (amounts in thousands). 4Q26 Financial Summary – (comparisons are versus the same prior year period) Revenues increased 2.6%Non-GAAP organic and core organic revenues1 growth was 2.6% and (0.6)%, respectivelyOperating income increased 87% to $2,748Non-GAAP adjusted operating income ("AOI") excluding unusual items2 increased 49.2% and was 28.7% as a percentag

    5/27/26 8:00:00 AM ET
    $MLAB
    Industrial Machinery/Components
    Industrials

    Mesa Laboratories Announces CEO Transition and Appointment of Siddhartha Kadia as President and CEO

    LAKEWOOD, Colo., March 09, 2026 (GLOBE NEWSWIRE) --  Mesa Laboratories, Inc. (NASDAQ:MLAB) ("Mesa" or "the Company"), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced that Gary Owens will step down as President and CEO on April 12, 2026, and will enable a smooth leadership transition. "Gary has served as Mesa's CEO since 2017, leading Mesa through a period of significant growth, expansion into new markets, the maturation of the company's foundation, and the implementation of The Mesa Way business system," said John Sullivan, Chair of the Board. "We are grateful for his leadership and wish him continued success." T

    3/9/26 4:30:00 PM ET
    $MLAB
    Industrial Machinery/Components
    Industrials

    AppLovin, Robinhood Markets and Emcor Group Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Sept. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 22, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space. Uber Technologies Inc. (NYSE:UBER) will replace Charter Communications Inc. (NASD: CHTR) in the S&P 100. Charter Communications will remain in the S&P 500.AppLovin Corp. (NASD: APP), Robinhood Markets Inc. (NASD: H

    9/5/25 6:34:00 PM ET
    $ACHC
    $APP
    $BGS
    Medical Specialities
    Health Care
    Computer Software: Programming Data Processing
    Technology

    $MLAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ladiwala Shiraz Shabanali bought $252,805 worth of shares (3,500 units at $72.23), increasing direct ownership by 70% to 8,523 units (SEC Form 4)

    4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)

    3/10/26 5:43:24 PM ET
    $MLAB
    Industrial Machinery/Components
    Industrials

    Director Capone Mark Christopher bought $99,331 worth of shares (1,301 units at $76.35), increasing direct ownership by 61% to 3,429 units (SEC Form 4)

    4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)

    3/10/26 3:46:59 PM ET
    $MLAB
    Industrial Machinery/Components
    Industrials

    Director Tripeny R Tony bought $99,940 worth of shares (1,315 units at $76.00), increasing direct ownership by 32% to 5,398 units (SEC Form 4)

    4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)

    3/10/26 3:39:49 PM ET
    $MLAB
    Industrial Machinery/Components
    Industrials

    $MLAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CAO Crennen Lyndsey Elizabeth sold $39,560 worth of shares (442 units at $89.50), exercised 726 shares at a strike of $95.10 and was granted 263 shares, increasing direct ownership by 37% to 2,020 units (SEC Form 4)

    4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)

    6/23/26 1:34:00 PM ET
    $MLAB
    Industrial Machinery/Components
    Industrials

    SVP Operations Archbold Brian David exercised 3,324 shares at a strike of $95.10, was granted 1,859 shares and sold $225,187 worth of shares (2,516 units at $89.50), increasing direct ownership by 72% to 6,377 units (SEC Form 4)

    4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)

    6/23/26 1:02:33 PM ET
    $MLAB
    Industrial Machinery/Components
    Industrials

    CFO Sakys John exercised 3,792 shares at a strike of $95.10, was granted 2,282 shares and sold $253,022 worth of shares (2,827 units at $89.50) as part of a pre-agreed trading plan, increasing direct ownership by 20% to 19,785 units (SEC Form 4)

    4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)

    6/23/26 12:23:10 PM ET
    $MLAB
    Industrial Machinery/Components
    Industrials

    $MLAB
    SEC Filings

    View All

    SEC Form DEF 14A filed by Mesa Laboratories Inc.

    DEF 14A - MESA LABORATORIES INC /CO/ (0000724004) (Filer)

    7/22/26 2:55:07 PM ET
    $MLAB
    Industrial Machinery/Components
    Industrials

    Mesa Laboratories Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - MESA LABORATORIES INC /CO/ (0000724004) (Filer)

    6/15/26 5:29:57 PM ET
    $MLAB
    Industrial Machinery/Components
    Industrials

    SEC Form S-8 filed by Mesa Laboratories Inc.

    S-8 - MESA LABORATORIES INC /CO/ (0000724004) (Filer)

    6/3/26 8:23:01 AM ET
    $MLAB
    Industrial Machinery/Components
    Industrials

    $MLAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mesa Laboratories upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Mesa Laboratories from Underweight to Equal Weight and set a new price target of $67.00

    8/7/25 7:05:04 AM ET
    $MLAB
    Industrial Machinery/Components
    Industrials

    Wells Fargo initiated coverage on Mesa Laboratories with a new price target

    Wells Fargo initiated coverage of Mesa Laboratories with a rating of Underweight and set a new price target of $120.00

    8/28/24 7:48:06 AM ET
    $MLAB
    Industrial Machinery/Components
    Industrials

    Mesa Laboratories upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Mesa Laboratories from In-line to Outperform and set a new price target of $125.00 from $100.00 previously

    1/4/24 8:29:10 AM ET
    $MLAB
    Industrial Machinery/Components
    Industrials

    $MLAB
    Financials

    Live finance-specific insights

    View All

    MESA LABS DECLARES QUARTERLY DIVIDEND

    Lakewood, Colo., July 06, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 15, 2026, to shareholders of record at the close of business on August 31, 2026. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, inc

    7/6/26 9:50:22 AM ET
    $MLAB
    Industrial Machinery/Components
    Industrials

    MESA LABS DECLARES QUARTERLY DIVIDEND

    LAKEWOOD, Colo., April 02, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 15, 2026, to shareholders of record at the close of business on May 29, 2026. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase pa

    4/2/26 6:00:00 PM ET
    $MLAB
    Industrial Machinery/Components
    Industrials

    MESA LABS DECLARES QUARTERLY DIVIDEND

    LAKEWOOD, Colo., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 16, 2026, to shareholders of record at the close of business on February 28, 2026. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increa

    1/7/26 5:00:00 PM ET
    $MLAB
    Industrial Machinery/Components
    Industrials

    $MLAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mesa Laboratories Inc.

    SC 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)

    10/15/24 1:29:56 PM ET
    $MLAB
    Industrial Machinery/Components
    Industrials

    SEC Form SC 13G/A filed by Mesa Laboratories Inc. (Amendment)

    SC 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)

    2/13/24 5:09:39 PM ET
    $MLAB
    Industrial Machinery/Components
    Industrials

    SEC Form SC 13G/A filed by Mesa Laboratories Inc. (Amendment)

    SC 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)

    1/23/24 2:18:26 PM ET
    $MLAB
    Industrial Machinery/Components
    Industrials